153 results
Page 3 of 8
DEF 14A
lfkkwi
9 Sep 20
Definitive proxy
4:00pm
8-K
EX-99.1
1yaatifp08
13 Aug 20
Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2021
8:30am
PRE 14A
bpnombt9
10 Aug 20
Preliminary proxy
12:00am
8-K
EX-99.1
h0gmwsdq
31 Jul 20
Regulation FD Disclosure
4:05pm
424B5
elu7s
7 Jul 20
Prospectus supplement for primary offering
4:32pm
10-K
95mi63psk
29 Jun 20
Annual report
4:02pm
10-K
EX-10.3
h7jmyi 05j
29 Jun 20
Annual report
4:02pm
10-K
EX-10.2
nq5zo
29 Jun 20
Annual report
4:02pm
8-K
EX-99.1
j3octd4hwhi
29 Jun 20
Acasti Pharma Provides Fiscal 2020 Year-End Business Update
12:50pm
S-3
EX-1.2
78davwb i18pxg2
29 Jun 20
Shelf registration
12:00am
S-3
pnqgqv4i
29 Jun 20
Shelf registration
12:00am
8-K
EX-99.1
yst9dbllo
19 Jun 20
Acasti Pharma Receives FDA Response to TRILOGY 1 Briefing Package
9:09am
8-K
EX-99.1
c5on3sw5qrlhwrh25
30 Apr 20
Acasti Pharma Announces Submission of TRILOGY 1 Briefing Package to FDA
4:22pm
8-K
EX-99.1
qec69u8tx5y54qw
20 Apr 20
Acasti Pharma Awarded Notice of Allowance for Second Composition of Matter Patent in Canada
4:05pm
8-K
EX-99.1
uww3d uhn1qw
1 Apr 20
Acasti Pharma Submits FDA Meeting Request on Schedule, and FDA Meeting Expected in the Second Half of June
5:12pm
6-K
EX-99.1
alkrgs9u5s34sruc qm5
11 Mar 20
Acasti Pharma Awarded Notice of Allowance for Additional Composition of Matter and Method of Use Patents in the United States and Mexico
8:00am
6-K
EX-99.1
5ipff xh1xoylqk6z
28 Feb 20
Acasti Receives NASDAQ Notification Regarding Minimum Bid Requirements
5:00pm
6-K
EX-99.1
cvc9 9249fll0lk6
14 Feb 20
Current report (foreign)
8:00am
6-K
EX-99.1
4qx8lh5uk37dyiz
14 Feb 20
Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2020
8:00am
6-K
EX-99.1
9yxrjzm7ug73gn vn1
13 Feb 20
Acasti Pharma Schedules Third Quarter Fiscal 2020 and Business Update Conference Call
9:00am